Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis
| Autor: | S Facchini, Alfredo Marinelli, Luca Scafuri, Nicola Longo, Sabino De Placido, Felice Crocetto, Guru Sonpavde, Giuseppe Lucarelli, Antonio Verde, Giuseppe Di Lorenzo, Ciro Imbimbo, Daniela Terracciano, Matteo Ferro, Pasquale Dolce, Angelo Vaia, Vincenzo Mirone, Carlo Buonerba, Liliana Montella |
|---|---|
| Přispěvatelé: | Buonerba, C., Ferro, M., Dolce, P., Crocetto, F., Verde, A., Lucarelli, G., Scafuri, L., Facchini, S., Vaia, A., Marinelli, A., Terracciano, D., Montella, L., Longo, N., Imbimbo, C., Mirone, V., Di Lorenzo, G., De Placido, S., Sonpavde, G. |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Oncology Male medicine.medical_specialty Docetaxel Disease-Free Survival 03 medical and health sciences chemistry.chemical_compound Prostate cancer 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols Apalutamide Enzalutamide Medicine Humans Castration Androgen Antagonist Abiraterone Castration-sensitive prostate cancer Randomized Controlled Trials as Topic Antineoplastic Combined Chemotherapy Protocol business.industry Hazard ratio Prostatic Neoplasms Androgen Antagonists Hematology medicine.disease Androgen receptor Clinical trial Prostatic Neoplasms Castration-Resistant 030104 developmental biology Treatment Outcome chemistry 030220 oncology & carcinogenesis Meta-analysis Prostatic Neoplasm business medicine.drug Human |
| Popis: | Background Both docetaxel and androgen-receptor-axis-targeted (ARAT) agents are approved in metastatic castration-sensitive prostate cancer (mCSPC) patients. Predictive factors of therapy efficacy are lacking. Methods We included articles reporting data about randomized-controlled clinical trials (RCTs) testing an ARAT agent plus ADT vs. ADT. We aimed to obtain pooled estimates of efficacy outcomes and assess differences in pooled estimates of efficacy outcomes between sub-groups. Results A total of 5427 mCSPC patients enrolled in five RCTs were evaluable for OS (Overall Survival) and PFS (Progression-free survival). Pooled OS-HR (Hazard Ratio) was 0.66 (95 % CI: 0.60−0.74), while pooled PFS-HR was 0.46 (95 % CI: 0.40−0.53). Combined treatment with docetaxel was associated with differential OS outcomes, while tumor volume according to the CHAARTED criteria and visceral metastasis were associated with differential PFS outcomes. Conclusion Our results add evidence that ARAT agents improve OS in mCSPC and discourage their combined use with docetaxel in this setting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|